Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Search for low mass Higgs bosons produced in Z0 decays

A search for light Higgs bosons was performed using the data sample collected in 1990 by the DELPHI detector at LEP, at centre of mass energies between 88.2 and 94.2 GeV. Using the process e+e-→H0+Z0*, Z0*→ff, it is possible to exclude the existence of the standard model Higgs particle with a mass between 0 and 210 MeV/c2 at the 99% confidence level. Extending this analysis to the minimal supersymmetric standard model restricts the lightest neutral Higgs boson to masses above 28 GeV/c2 irrespective of the value of the mixing angle. © 1991 Springer-Verlag

Multiplicity dependence of mean transverse momentum in e+ e- annihilations at LEP energies

A strong increase of the mean transverse momentum 〈pt〉 with the number of charged particles nch is observed in e+e- annihilations into hadrons at LEP energies. The effect resembles correlations observed in hadron-hadron interactions. In e+e- annihilations the 〈pt〉 and nch correlations can be accounted for by gluon radiation.0SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Determination of 55-155-155-1in second order QCD from hadronic Z decays

Distributions of event shape variables obtained from 120600 hadronic Z decays measured with the DELPHI detector are compared to the predictions of QCD based event generators. Values of the strong coupling constant αs are derived as a function of the renormalization scale from a quantitative analysis of eight hadronic distributions. The final result, αs(MZ), is based on second order perturbation theory and uses two hadronization corrections, one computed with a parton shower model and the other with a QCD matrix element model. © 1992 Springer-Verlag